Bruce G. Redman

14.3k total citations · 3 hit papers
143 papers, 9.1k citations indexed

About

Bruce G. Redman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bruce G. Redman has authored 143 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 64 papers in Pulmonary and Respiratory Medicine and 34 papers in Molecular Biology. Recurrent topics in Bruce G. Redman's work include Renal cell carcinoma treatment (40 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Immunotherapy and Immune Responses (22 papers). Bruce G. Redman is often cited by papers focused on Renal cell carcinoma treatment (40 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Immunotherapy and Immune Responses (22 papers). Bruce G. Redman collaborates with scholars based in United States, Canada and China. Bruce G. Redman's co-authors include Robert J. Motzer, Brian I. Rini, M. Dror Michaelson, George Wilding, Daniel J. George, Gary R. Hudes, Charles M. Baum, Kim Margolin, Sindy T. Kim and Michelle S. Ginsberg and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bruce G. Redman

142 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

2005 1.3k citations Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology profile →
Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2006 969 citations Robert J. Motzer, Brian I. Rini et al. profile →
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

2014 865 citations Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruce G. Redman United States	46	4.7k	3.8k	3.4k	2.1k	1.8k	143	9.1k
William L. Dahut United States	56	5.2k 1.1×	4.3k 1.1×	3.2k 0.9×	2.8k 1.4×	1.6k 0.9×	291	10.4k
Hans Prenen Belgium	41	4.0k 0.9×	2.6k 0.7×	2.6k 0.8×	1.3k 0.6×	1.6k 0.9×	207	8.6k
Vassilis Georgoulias Greece	48	4.9k 1.0×	2.7k 0.7×	2.8k 0.8×	785 0.4×	2.4k 1.3×	296	8.3k
David S. Schrump United States	55	2.8k 0.6×	1.8k 0.5×	4.0k 1.2×	1.9k 0.9×	1.1k 0.6×	194	8.8k
Patricia Keegan United States	54	5.0k 1.1×	3.1k 0.8×	2.1k 0.6×	1.3k 0.6×	1.6k 0.9×	140	9.3k
Michael Millward Australia	48	4.4k 0.9×	1.9k 0.5×	3.2k 1.0×	1.2k 0.6×	1.3k 0.7×	277	7.7k
Hans J. Hammers United States	46	4.4k 0.9×	4.1k 1.1×	3.0k 0.9×	1.2k 0.6×	1.9k 1.0×	216	8.1k
Olivier Rixe France	44	4.9k 1.0×	5.7k 1.5×	5.3k 1.6×	898 0.4×	2.8k 1.5×	205	11.3k
Joseph P. Eder United States	47	8.2k 1.8×	3.2k 0.8×	3.4k 1.0×	2.9k 1.4×	1.6k 0.9×	178	12.2k
Ronit Simantov United States	36	3.3k 0.7×	4.3k 1.1×	5.5k 1.6×	1.4k 0.7×	2.6k 1.5×	88	11.2k

Countries citing papers authored by Bruce G. Redman

Since Specialization

Citations

This map shows the geographic impact of Bruce G. Redman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce G. Redman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce G. Redman more than expected).

Fields of papers citing papers by Bruce G. Redman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce G. Redman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce G. Redman. The network helps show where Bruce G. Redman may publish in the future.

Co-authorship network of co-authors of Bruce G. Redman

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce G. Redman. A scholar is included among the top collaborators of Bruce G. Redman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce G. Redman. Bruce G. Redman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tan, Meng H., Kara Mizokami‐Stout, Sarah Yentz, et al.. (2019). Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. SHILAP Revista de lepidopterología. 5(1). 1–1. 129 indexed citations

Thompson, John A., Robert J. Motzer, Ana M. Molina, et al.. (2018). Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research. 24(18). 4399–4406. 48 indexed citations

Powles, T.B., Bernard Escudier, Paul de Souza, et al.. (2016). Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial. Annals of Oncology. 27. vi284–vi284. 1 indexed citations

Motzer, Robert J., Brian I. Rini, David F. McDermott, et al.. (2014). Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 33(13). 1430–1437. 865 indexed citations breakdown →

Rini, Brian I., Bruce G. Redman, J. Garcia, et al.. (2014). A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Annals of Oncology. 25(9). 1794–1799. 9 indexed citations

Filson, Christopher P., Bruce G. Redman, Rodney L. Dunn, & David C. Miller. (2011). Initial Patterns of Care With Oral Targeted Therapies for Patients With Renal Cell Carcinoma. Urology. 77(4). 825–830.e1. 17 indexed citations

Kryczek, Ilona, Rebecca Liu, Guobin Wang, et al.. (2009). FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease. Cancer Research. 69(9). 3995–4000. 151 indexed citations

Houk, Brett E., Carlo L. Bello, George D. Demetri, et al.. (2008). Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches. Cancer Research. 68. 5828–5828. 4 indexed citations

Motzer, Robert J., M. Dror Michaelson, Bruce G. Redman, et al.. (2005). Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(1). 16–24. 1304 indexed citations breakdown →

10.

Vaishampayan, Ulka N., James R. Faulkner, Eric J. Small, et al.. (2005). Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma. Cancer. 104(8). 1627–1632. 43 indexed citations

11.

Atkins, Michael B., Bruce G. Redman, J W Mier, et al.. (2001). A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.. PubMed. 7(3). 486–92. 34 indexed citations

12.

Redman, Bruce G. & Alfred E. Chang. (2000). Advanced renal cell carcinoma. Current Treatment Options in Oncology. 1(5). 417–422. 1 indexed citations

13.

Johnson, Timothy M., Alfred E. Chang, Bruce G. Redman, et al.. (2000). Management of melanoma with a multidisciplinary melanoma clinic model. Journal of the American Academy of Dermatology. 42(5). 820–826. 21 indexed citations

14.

Smith, David C., Bruce G. Redman, Lawrence E. Flaherty, et al.. (1998). A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 52(2). 257–260. 137 indexed citations

15.

Pienta, Kenneth J., Bruce G. Redman, Peggy S. Esper, & Lawrence E. Flaherty. (1996). A Phase II Evaluation of Oral Tamoxifen and Intermittent Intravenous Vinblastine in Hormone-Refractory Adenocarcinoma of the Prostate. American Journal of Clinical Oncology. 19(5). 500–503. 8 indexed citations

16.

Honn, Kenneth V., Yong Q. Chen, Michael L. Cher, et al.. (1996). Prostate cancer old problems and new approaches. Pathology & Oncology Research. 2(4). 276–292. 5 indexed citations

17.

Mohammad, Ramzi M., et al.. (1995). Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leukemia Research. 19(9). 667–673. 49 indexed citations

18.

Haas, Gabriel P., et al.. (1993). Immunotherapy for Metastatic Renal Cell Cancer: Effect on the Primary Tumor. Journal of Immunotherapy. 13(2). 130–135. 16 indexed citations

19.

Poplin, Elizabeth, Thomas H. Corbett, Lawrence E. Flaherty, et al.. (1992). Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study. Investigational New Drugs. 10(3). 165–170. 68 indexed citations

20.

Flaherty, Lawrence E., Antoinette J. Wozniak, Bruce G. Redman, et al.. (1991). 5-fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer. Cancer. 68(5). 944–947. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact